Relay Therapeutics (RLAY) Cash & Equivalents (2019 - 2026)

Relay Therapeutics (RLAY) has reported Cash & Equivalents for 8 consecutive years, with $204.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Equivalents rose 118.71% year-over-year to $204.6 million; the TTM figure through Mar 2026 stood at $204.6 million (up 118.71% YoY), while the FY2025 annual figure was $84.0 million, down 32.4% from the prior year.
• Cash & Equivalents grew to $204.6 million in Q1 2026 per RLAY's latest filing, from $84.0 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $354.6 million in Q3 2022 and bottomed at $84.0 million in Q4 2025.
• Historically, Cash & Equivalents has averaged $146.3 million across 5 years, with a median of $143.7 million in 2023.
• Annual changes were most pronounced in 2022 — Cash & Equivalents slumped 58.57% — and 2026, when it surged 118.71%.
• Relay Therapeutics' Cash & Equivalents stood at $151.8 million in 2022, then decreased by 5.31% to $143.7 million in 2023, then fell by 13.53% to $124.3 million in 2024, then slumped by 32.4% to $84.0 million in 2025, then soared by 143.51% to $204.6 million in 2026.
• Business Quant data shows RLAY's Cash & Equivalents at $204.6 million in Q1 2026, $84.0 million in Q4 2025, and $91.6 million in Q3 2025.